Aline Clavert

机构：Centre Hospitalier Universitaire d'Angers · ORCID：0000-0003-1270-848X

发表论文 80 篇 · 总被引 1620 次 · h-index 18

代表论文

• Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network (2019 · European Journal of Cancer · 被引 324)
• Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (2018 · The Lancet Oncology · 被引 164)
• Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia (2021 · Blood Advances · 被引 52)
• Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO) (2020 · HemaSphere · 被引 42)
• RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells (2018 · Haematologica · 被引 39)
• Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network (2016 · Blood · 被引 37)